Register  |  Login
Jeffrey A. LIEBERMAN Jeffrey A. Lieberman, M.D. Chairman, Department of Psychiatry, College of Physicians and Surgeons, Columbia University Director, New York State Psychiatric Institute Director, Lieber Center for Schizophrenia Research New York, USA Email: Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975. He received his postgraduate training in psychiatry at St. Vincent’s Hospital and Medical Center of New York Medical College. Dr. Lieberman, MD, currently is the Lawrence E. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. He also holds the Lieber Chair and Directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia University. Prior to moving to Columbia University he was Vice Chairman for Research and Scientific Affairs in the Department of Psychiatry and Director of the Mental Health and Neuroscience Center at the University of North Carolina at Chapel Hill School of Medicine. Dr. Lieberman’s research focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. Dr. Lieberman served as the Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), sponsored by the NIMH, and one of the most important studies ever conducted. He is currently serving as the Principal Investigator on the NIMH contract Recovery After an Initial Schizophrenia Episode (RAISE) and will lead a multi-institution research team in developing and testing an evidence-based strategic intervention for early psychosis to demonstrate how treatment at the onset of symptoms can prevent effects of schizophrenia and related psychotic disorders. In collaboration with The University of North Carolina, Dr. Lieberman leads the Clozapine-Induced Agranulocytosis Consortium (CIAC) project at Columbia University as a newly awarded NIMH addition to the Genome-Wide Association Study to Detect Genetic Variation for Schizophrenia aiming to detect genetic markers that predict side effect vulnerability, including that for agranulocytosis caused by antipsychotic drugs. His work has been reported in more than 500 articles in the scientific literature and he has edited or co-edited eight books. He also serves, or has served, as Associate Editor of the American Journal of Psychiatry and Biological Psychiatry, among many others. He is or has been a member of the advisory committee for Neuropharmacologic and Psychopharmacologic Drugs of the Food and Drug Administration, the Planning Board for the Surgeon General’s Report on Mental Health, the Committee on Research on Psychiatric Treatments of the American Psychiatric Association (APA), the APA Work Group for the Development of Schizophrenia Treatment Guidelines, among other national organizations. He currently chairs the APA Council of Research, is a member of the board of directors of the American Psychiatric Foundation of the APA along with other professional organizations. Dr. Lieberman is a recipient of a huge number of prizes for his outstanding research, and he currently lives with his wife and two sons in New York City.